Loading
Most people with cancer are over 65, but most trial patients are younger and fitter. A dedicated fund would pay for trials designed for the patients we actually treat.
Public and charitable funders create a standing fund for trials with inclusive eligibility (age, kidney function, performance status, comorbidity), geriatric assessment-guided dosing, and endpoints that matter to older adults (function, independence, time at home). Trials would test dose reductions, shorter courses and de-escalation of standard regimens in patients over 70, where retrospective data suggest toxicity and discontinuation are far higher than in trials. Industry has little incentive to run these because they mostly test less drug.
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated, Trials do not represent the people who get cancer.
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated, Trials do not represent the people who get cancer.
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated, Trials do not represent the people who get cancer.
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated, Trials do not represent the people who get cancer.
Shares Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials, Geriatric assessment, Funding follows fashion, not burden.
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated.
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated.
Shares Geriatric assessment, Older and multimorbid patients are excluded and undertreated.